Large Outflow of Money Witnessed in Astrazeneca PLC

Astrazeneca PLC (AZN) : Net money flow in Astrazeneca PLC (AZN) was negative ($1.57 million) and the inflow of money on uptick was $0.2 million, whereas, the outflow of money on downticks amounted to $1.77 million on Friday. The traders used every opportunity of price strength in the stock to sell their positions, hence, the total uptick to downtick ratio was 0.11. The block trades show that the large investors, were aggressive sellers in the stock. On the other hand, the total value of block trades done on downticks was $1.44 million. The money flow in block trades was negative ($1.44). Astrazeneca PLC (AZN) gained $0.41 cent during the day and reached $33.01, a gain of 1.26% over the previous day.


Institutional Investors own 11.72% of Astrazeneca PLC shares.

Astrazeneca PLC (NYSE:AZN): The stock opened at $33.08 and touched an intraday high of $33.4769 on Friday. During the day, the stock corrected to an intraday low of $32.96, however, the bulls stepped in and pushed the price higher to close in the green at $33.31 with a gain of 2.18% for the day. The total traded volume for the day was 3,646,805. The stock had closed at $32.6 in the previous trading session.

Astrazeneca PLC (AZN) has been under a strong bear grip, hence the stock is down -2.7% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.28% in the past 1 week. The stock has risen by 0.79% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.83% in the past 4 weeks.

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.